Loading...

WP4 LOI accepted by the FDA!

2020-04-08T13:23:27+00:00April 8th, 2020|Latest News|

The TransBioLine WP4 (Biomarkers of vascular injury) Letter of Intent was accepted by the FDA on February 2020 and the team is in preparation to discuss the FDA recommendations to [...]

2nd Consortium Meeting

2019-10-23T14:45:38+00:00September 1st, 2019|Latest News|

TransBioLine Consortium met in Sitges, Barcelona, on the 30th September and 1st October 2019. Members of the 27 partners of the Consortium met in Sitges to report on progress during the first half year of [...]

TransBioLine Kick off Meeting

2019-09-10T15:08:30+00:00April 20th, 2019|Latest News|

From February 28th to March 1st 2019 participants from the 27 partners of the Consortium met during two full days to begin a new adventure. The meeting took place in Basel, Switzerland, in Novartis premises [...]

ABOUT IMI

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences.

ACKNOWLEDGEMENT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies.

IMI Europa
info@transbioline.com
© Copyright    |   TransBioLine   |   Disclaimer: The TransBioLine website reflects the author’s view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.
FacebookTwitterInstagram
This website uses cookies and third party services. Ok